Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Corrigendum: Magnetic Resonance Elastography and Diffusion Weighted Imaging in the Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
Leung, Fiona P., Alsaif, Hind S. , Lim, Seng Gee , Wee, Aileen , Venkatesh, Sudhakar K. , Venkatesh, Sudhakar K , Hennedige, Tiffany Priyanthi , Wang, Gang , Teo, Lynette

Mayo Clinic

Gut and Liver | July 13, 2020 | Volume: 14 | Issue: 4 | Pages: 532-532

10.5009/gnl14041 | PMID 32655018 Get It

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Foss, Francine M. , Wang, Victoria , Luger, Selina M. , Miller, Kenneth B., Stadtmauer, Edward A. , Avigan, David , Gascoyne, Randall D., Wagner, Henry, Strair, Roger , Sprague, Kellie , Litzow, Mark R. , Tallman, Martin S. , Horning, Sandra J., Foss, Francine , Jegede, Opeyemi A. , Whiteside, Theresa L , Arber, Daniel A. , Hogan, William J. , Lazarus, Hillard M.

Mayo Clinic

Transfusion | July 12, 2020 | Volume: 60 | Issue: 8 | Pages: 1867-1872

10.1111/trf.15798 | PMID 32654201 Get It

BackgroundExtracorporeal photopheresis (ECP) is an immunomodulatory cellular therapy which has been shown to induce a tolerogenic state in patients with acute and chronic graft‐vs‐host disease. ECOG‐ACRIN explored the activity of ECP as a part of a reduced intensity conditioning regimen in two multicenter trials in patients with MDS (E1902) and lymphomas (E1402). While both studies closed before completing accrual, we report results in 23 patients (17 MDS and 6 lymphoma).Study Design and MethodsPatients received 2 days of ECP followed by pentostatin 4 mg/m2 /day for two consecutive days, followed by 600 cGy of total body irradiation prior to stem cell infusion. Immunosuppression for aGVHD was infusional cyclosporine A or tacrolimus and methotrexate on day +1, +3, with mycophenolate mofetil starting on day 100 for chronic GVHD prophylaxis.ResultsAll patients engrafted, with median time to neutrophil and platelet engraftment of 15‐18 days and 10‐18 days respectively. Grade 3 or 4 aGVHD occurred in 13% and chronic extensive GVHD in 30%.ConclusionsThese studies demonstrate that ECP/pentostatin/TBI is well tolerated and associated with adequate engraftment of neutrophils and platelets in patients with lymphomas and MDS.
Exploratory Genome-Wide Interaction Analysis of Nonsteroidal Anti-inflammatory Drugs and Predicted Gene Expression on Colorectal Cancer Risk
Petersen, Paneen S., Schmit, Stephanie L. , Drew, David A. , Berndt, Sonja I. , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Gallinger, Steven , Gruber, Stephen B. , Haile, Robert W. , Harrison, Tabitha A. , Hoffmeister, Michael , Jacobs, Eric J. , Joshi, Amit D. , Li, Li , Lindor, Noralane M. , Martín, Vicente , Maclnnis, Robert J., Moreno, Vı́ctor , Nan, Hongmei , Rennert, Gad , Slattery, Martha L. , Thibodeau, S. N., Weinstein, Stephanie J. , Woods, Michael O. , Peters, Ulrike , Brenner, Hermann , Rennert, Gad , Drew, David A , Brenner, Hermann , Gruber, Stephen B , Haile, Robert W , Harrison, Tabitha A , Hoffmeister, Michael , Martín, Vicente , Milne, Roger L , Maclnnis, Robert , Moreno, Victor , Potter, John D , Rennert, Gad , Slattery, Martha L , Thibodeau, Steve N, Weinstein, Stephanie J , Rennert, Gad , Brenner, Hermann , Nan, Hongmei , Wang, Xiaoliang , Su, Yu-Ru , Bien, Stephanie A. , Albanes, Demetrius , Campbell, Peter T. , Jenkins, Mark A. , Lin, Yi , Marchand, Loı̈c Le , Milne, Roger L. , Newcomb, Polly A. , Potter, John D. , Chan, Andrew T. , White, Emily , Hsu, Li

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | July 10, 2020 | Volume: 29 | Issue: 9 | Pages: 1800-1808

10.1158/1055-9965.epi-19-1018 | PMID 32651213 Get It

Abstract Background: Regular use of nonsteroidal anti-inflammatory drugs (NSAID) is associated with lower risk of colorectal cancer. Genome-wide interaction analysis on single variants (G × E) has identified several SNPs that may interact with NSAIDs to confer colorectal cancer risk, but variations in gene expression levels may also modify the effect of NSAID use. Therefore, we tested interactions between NSAID use and predicted gene expression levels in relation to colorectal cancer risk. Methods: Genetically predicted gene expressions were tested for interaction with NSAID use on colorectal cancer risk among 19,258 colorectal cancer cases and 18,597 controls from 21 observational studies. A Mixed Score Test for Interactions (MiSTi) approach was used to jointly assess G × E effects which are modeled via fixed interaction effects of the weighted burden within each gene set (burden) and residual G × E effects (variance). A false discovery rate (FDR) at 0.2 was applied to correct for multiple testing. Results: Among the 4,840 genes tested, genetically predicted expression levels of four genes modified the effect of any NSAID use on colorectal cancer risk, including DPP10 (PG×E = 1.96 × 10−4), KRT16 (PG×E = 2.3 × 10−4), CD14 (PG×E = 9.38 × 10−4), and CYP27A1 (PG×E = 1.44 × 10−3). There was a significant interaction between expression level of RP11-89N17 and regular use of aspirin only on colorectal cancer risk (PG×E = 3.23 × 10−5). No interactions were observed between predicted gene expression and nonaspirin NSAID use at FDR &lt; 0.2. Conclusions: By incorporating functional information, we discovered several novel genes that interacted with NSAID use. Impact: These findings provide preliminary support that could help understand the chemopreventive mechanisms of NSAIDs on colorectal cancer.
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
Barman, Poulami , Shepherd, Lois E. , Goss, Paul E. , Buzdar, Aman U. , Cairns, Junmei , Casey, Abraham Eyman, Goodnature, Barbara, Haddad, Tufia C. , Weinshilboum, Richard M. , Wang, Liewei , Eyman Casey, Abraham, Hoskin, Tanya L. , Goodnature, Barbara A, Ingle, James N. , Kalari, Krishna R. , Ellis, Matthew J. , Robson, Mark E. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M.

Mayo Clinic

Pharmacogenetics and Genomics | July 9, 2020 | Volume: 31 | Issue: 1 | Pages: 1-9

10.1097/fpc.0000000000000415 | PMID 32649577 Get It

Objectives Based on our previous findings that postmenopausal women with estrone (E1) and estradiol (E2) concentrations at or above 1.3 pg/ml and 0.5 pg/ml, respectively, after 6 months of adjuvant anastrozole therapy had a three-fold risk of recurrence, we aimed to identify a single-nucleotide polymorphism (SNP)-based model that would predict elevated E1 and E2 and then validate it in an independent dataset. Patients and methods The test set consisted of 322 women from the M3 study and the validation set consisted of 152 patients from MA.27. All patients were treated with adjuvant anastrozole, had on-anastrozole E1 and E2 concentrations and genome-wide genotyping. Results SNPs were identified from the M3 genome-wide association study. The best model to predict the E1-E2 phenotype with high balanced accuracy was a support vector machine model using clinical factors plus 46 SNPs. We did not have an independent cohort that is similar to the M3 study with clinical, E1-E2 phenotypes and genotype data to test our model. Hence, we chose a nested matched case-control cohort (MA.27 study) for testing. Our E1-E2 model was not validated but we found the MA.27 validation cohort was both clinically and genomically different. Conclusions We identified a SNP-based model that had excellent performance characteristics for predicting the phenotype of elevated E1 and E2 in women treated with anastrozole. This model was not validated in an independent dataset but that dataset was clinically and genomically substantially different. The model will need validation in a prospective study.
The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma
Buckarma, EeeLN H. , Werneburg, Nathan W., Conboy, Caitlin B. , Kabashima, Ayano , O’Brien, Daniel R. , Wang, Chen , Smoot, Rory L. , Smoot, Rory L , Wang, Chen , Conboy, Caitlin B , Ilyas, Sumera I.

Mayo Clinic

Molecular Cancer Research | July 9, 2020 | Volume: 18 | Issue: 10 | Pages: 1574-1588

10.1158/1541-7786.mcr-20-0165 | PMID 32646966 Get It

Abstract The Hippo pathway effector Yes-associated protein (YAP) is localized to the nucleus and transcriptionally active in a number of tumor types, including a majority of human cholangiocarcinomas. YAP activity has been linked to chemotherapy resistance and has been shown to rescue KRAS and BRAF inhibition in RAS/RAF-driven cancers; however, the underlying mechanisms of YAP-mediated chemoresistance have yet to be elucidated. Herein, we report that the tyrosine phosphatase SHP2 directly regulates the activity of YAP by dephosphorylating pYAPY357 even in the setting of RAS/RAF mutations, and that diminished SHP2 phosphatase activity is associated with chemoresistance in cholangiocarcinomas. A screen for YAP-interacting tyrosine phosphatases identified SHP2, and characterization of cholangiocarcinomas cell lines demonstrated an inverse relationship between SHP2 levels and pYAPY357. Human sequencing data demonstrated lower SHP2 levels in cholangiocarcinomas tumors as compared with normal liver. Cell lines with low SHP2 expression and higher levels of pYAPY357 were resistant to gemcitabine and cisplatin. In cholangiocarcinomas cells with high levels of SHP2, pharmacologic inhibition or genetic deletion of SHP2 increased YAPY357 phosphorylation and expression of YAP target genes, including the antiapoptotic regulator MCL1, imparting resistance to gemcitabine and cisplatin. In vivo evaluation of chemotherapy sensitivity demonstrated significant resistance in xenografts with genetic deletion of SHP2, which could be overcome by utilizing an MCL1 inhibitor. Implications: These findings demonstrate a role for SHP2 in regulating YAP activity and chemosensitivity, and suggest that decreased phosphatase activity may be a mechanism of chemoresistance in cholangiocarcinoma via a MCL1-mediated mechanism.
Dietary Intake Is Associated With Ankle-brachial Index, Inflammation, And Ambulation In Peripheral Artery Disease Patients
Montgomery, Polly S., Palacios, Fedrico Silva-, Knehans, Allen, Wang, Ming , Shen, Biyi , Casanegra, Ana I. , Gardner, Andrew W.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 1074-1074

10.1249/01.mss.0000687316.54687.03 Get It

Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
Wen, Zhi , Rajagopalan, Adhithi , Flietner, Evan, Yun, Grant, Chesi, Marta , Furumo, Quinlan, Burns, Robert T., Papadas, Athanasios , Ranheim, Erik A. , Pagenkopf, Adam , Morrow, Zachary , Finn, Remington, Zhou, Yun , Li, Shuyi , Jensen, Jeffrey L. , Yu, Mei , Cicala, Alexander , Menting, James, Mitsiades, Constantine S. , Bergsagel, P. Leif , Wang, Demin , Asimakopoulos, Fotis , Zhang, Jing , Bergsagel, P. Leif , Wang, Demin , Burns, Robert T., You, Xiaona , Yu, Mei, Callander, Natalie S.

Mayo Clinic

Blood | July 8, 2020 | Volume: 137 | Issue: 1 | Pages: 61-74

10.1182/blood.2020007156 | PMID 32640012 Get It

Abstract NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61R and an MYC transgene in germinal center (GC) B cells (VQ mice). VQ mice developed a highly malignant MM characterized by a high proliferation index, hyperactivation of extracellular signal-regulated kinase and AKT signaling, impaired hematopoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved programmed cell death protein 1 and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain immune-checkpoint pathways, and expression of human high-risk MM gene signatures. VQ MM mice recapitulate most of the biological and clinical features of human advanced/high-risk MM. These MM phenotypes are serially transplantable in syngeneic recipients. Two MM cell lines were also derived to facilitate future genetic manipulations. Combination therapies based on MEK inhibition significantly prolonged the survival of VQ mice with advanced-stage MM. Our study provides a strong rationale to develop MEK inhibition–based therapies for treating advanced/relapsed MM.
Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk
Yuan, Fangcheng , Hung, Rayjean J. , Walsh, Naomi , Wheeler, William , Song, Lei , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hartge, Patricia, Hassan, Manal M. , Holly, Elizabeth A. , Hoover, Robert N. , Kirsten, Holger , Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Ng, Kimmie , Oberg, Ann L. , Porta, Miquel , Rabe, Kari G. , Real, Francisco X. , Rothman, Nathaniel , Sesso, Howard D. , Thompson, Ian M. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Zeleniuch‐Jacquotte, Anne , Shi, Jianxin , Li, Donghui , Petersen, Gloria M. , Wolpin, Brian M. , Platz, Elizabeth A. , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Bamlet, William R , Brennan, Paul , Hackert, Thilo , Katzke, Verena , Kirsten, Holger , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Li, Donghui , Klein, Alison P , Stolzenberg-Solomon, Rachael , Chaffee, Kari G. , Hung, Rayjean J , Visvanathan, Kala , Yuan, Fangcheng , Murphy, Neil , Porta, Miquel , Real, Francisco X , Thompson, Ian M , Zeleniuch-Jacquotte, Anne , Zhang, Han , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , Rosendahl, Jonas , Shu, Xiao‐Ou , White, Emily , Zheng, Wei , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Silverman, Debra T. , Wang, Xiaoliang , Wilkens, Lynne R. , Yu, Kai , Duell, Eric J. , Ámundadóttir, Laufey T. , Risch, Harvey A. , Klein, Alison P. , Stolzenberg‐Solomon, Rachael Z.

Mayo Clinic

Cancer Research | July 8, 2020 | Volume: 80 | Issue: 18 | Pages: 4004-4013

10.1158/0008-5472.can-20-0447 | PMID 32641412 Get It

Abstract Registry-based epidemiologic studies suggest associations between chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma (PDAC). As genetic susceptibility contributes to a large proportion of chronic inflammatory intestinal diseases, we hypothesize that the genomic regions surrounding established genome-wide associated variants for these chronic inflammatory diseases are associated with PDAC. We examined the association between PDAC and genomic regions (±500 kb) surrounding established common susceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac disease, chronic pancreatitis, and primary sclerosing cholangitis. We analyzed summary statistics from genome-wide association studies data for 8,384 cases and 11,955 controls of European descent from two large consortium studies using the summary data-based adaptive rank truncated product method to examine the overall association of combined genomic regions for each inflammatory disease group. Combined genomic susceptibility regions for ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis were associated with PDAC at P values &lt; 0.05 (0.0040, 0.0057, 0.011, and 3.4 × 10−6, respectively). After excluding the 20 PDAC susceptibility regions (±500 kb) previously identified by GWAS, the genomic regions for ulcerative colitis, Crohn disease, and inflammatory bowel disease remained associated with PDAC (P = 0.0029, 0.0057, and 0.0098, respectively). Genomic regions for celiac disease (P = 0.22) and primary sclerosing cholangitis (P = 0.078) were not associated with PDAC. Our results support the hypothesis that genomic regions surrounding variants associated with inflammatory intestinal diseases, particularly, ulcerative colitis, Crohn disease, inflammatory bowel disease, and chronic pancreatitis are associated with PDAC. Significance: The joint effects of common variants in genomic regions containing susceptibility loci for inflammatory bowel disease and chronic pancreatitis are associated with PDAC and may provide insights to understanding pancreatic cancer etiology.
The Functional Significance of the Metabolic Switch for the Activation of Mouse and Human Macrophages with Lipopolysaccharide
Wang, F., Zhang, S., Jiang, Xintong , Dzeja, Petras D., Herrmann, Joerg , Vučković, Ivan , Jeon, Ryoung‐Hoon , Lerman, Amir , Folmes, Clifford D.L.

Mayo Clinic

D33. SEPSIS IMMUNOLOGY | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6506-A6506

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6506 Get It